European markets without momentum, eyes riveted on Ukraine

Paris fell by 0.50% and Frankfurt flexes 0.18%. London clips 0.21%. Milan remains relatively stable (-0.03%), just like Zurich (-0.02%).

The global scholarships are cautiously evolved on Monday, as the meeting between Volodymyr Zelensky and Donald Trump approaches, pending advances in the war in Ukraine.

In Europe, the Paris Stock Exchange fell 0.50% and that of Frankfurt by 0.18%. London took 0.21%. Milan remained stable (-0.03%). In Zurich, the SMI marginally gave up 0.02%.

At Wall Street, around 3:50 pm GMT, the Dow Jones remained stable (-0.01%), the Nasdaq took 0.15%and the S&P 500 0.07%.

Ukrainian President Volodymyr Zelensky called on Russia to “put an end to this war which she herself triggered”, a few hours before her meeting in Washington on Monday with American president Donald Trump, who wants to push kyiv to territorial concessions.

Several European leaders will be present in Washington to support the position of the Ukrainian leader, summoned by the American president to accept concessions after his historic summit with Vladimir Putin on Friday in Alaska.

A ceasefire “would have the advantage of lifting uncertainty and boosting confidence, especially in European markets,” said Charlotte de Montpellier, economist at ING, interviewed by AFP.

The European defense sector in green

“The prospect of an agreement which +reward +(…) Assault rather than dissuading it will only strengthen the determination of European capitals to rearm,” said John Plassard, head of the investment strategy at Cité Gestion Private Bank.

The defense sector took advantage of this prospect in Europe: Leonardo took 3.16% in Milan and Bae Systems 1.82% in London. In Frankfurt, Hensoldt took 3.15%, Thyssenkrupp 4.29%and Rheinmetall 2.16%. SAAB took 4.47% at Stockholm.

Ukrainian President Volodymyr Zelensky said on Monday that Russia should not be “rewarded” for his war.

Oil and gold also suspended in Ukraine

The prices of oil oscillate with on the one hand “the prospect of reinforced sanctions against Russia (which) fades” with the peace negotiations in Ukraine, and on the other, a “climate of uncertainty” which persists, notes Susannah Streeter.

Around 3:45 p.m. GMT, the Brent of the Northern Sea barrel took 0.36% at 66.09 dollars. Its American equivalent, the barrel of West Texas Intermediate, gained 0.31% at 63.00 dollars.

In the gold market, investors are also closely monitoring geopolitical development in that it could influence the demand for refuge assets. The ounce remained stable (-0.01%) to 3,335.61 dollars.

Jackson Hole in the viewfinder

Another major major major point of attention: the Jackson Hole (Wyoming) conference, which brings together many central bankers at the end of the week, with a long -awaited speech by the President of the American Federal Reserve (Fed), Jerome Powell.

Despite Donald Trump’s pressure, the latter, for the moment, refuses to lower rates in the United States, while waiting to see more clearly on the effects on inflation of the customs duties imposed by the American president.

In this context, around 3:45 p.m. GMT, the yield at ten years of the American loan reached 4.34%, against 4.32% the day before at the end. At two years, the deadline most sensitive to changes in monetary policy, reached 3.77%, against 3.75%.

On the exchange market, the greenback took 0.29% against the euro, at 1.1672 dollars for one euro.

Bayer concludes agreements on PCB pollutants

The Monsanto group, a subsidiary of the German Bayer chemistry giant (+2.64% to 27.76 euros in Frankfurt) concluded a “agreement in principle” to settle the case in the United States with 200 complainants concerning damage caused by an exposure to polychlorobiphenyls (PCB), a product marketed by the company, on the Sky Valley school campus.

Novo Nordisk well oriented

The Danish pharmaceutical laboratory Novo Nordisk (+6.63% to 347.50 Danish crowns) was carried by the US Food and Pharmaceutical Products (FDA) approval of the use of its Wegovy anti-obsity medication to treat a liver disease.

Comments (0)
Add Comment